DGCR6L

Across TCGA pan-cancer cohorts, DGCR6L RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of DGCR6L’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where DGCR6L RNA is more highly expressed in tumor relative to normal tissue. In most cancer types DGCR6L is over-expressed in tumor, although a few such as KIRP and KICH show the opposite, repressed pattern.

HNSC, KIRP, and KICH are the cancer types where DGCR6L tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DGCR6L RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+0.681	<.001	8	view →
KIRP	All	All	−0.508	<.001	7	view →
KICH	Female	All	−0.803	<.001	5	view →
LUSC	All	All	+0.565	<.001	5	view →
BLCA	Female	All	+0.430	.029	3	view →
BRCA	All	III,IV	+0.436	.035	2	view →
LIHC	Male	All	+0.321	.030	2	view →
KIRC	Female	IV	+0.483	.029	1	view →
COAD	All	IV	−0.352	.039	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

DGCR6L–HNSC

Open the HNSC breakdown →